Meaghan E Killeen Selected Research

Inflammation (Inflammations)

1/2021	Electrophilic nitro-fatty acids suppress psoriasiform dermatitis: STAT3 inhibition as a contributory mechanism.
12/2018	Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.
1/2018	Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation.
4/2013	Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.
10/2009	Extracellular activation of arginase-1 decreases enterocyte inducible nitric oxide synthase activity during systemic inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Meaghan E Killeen Research Topics

Disease

5	Inflammation (Inflammations) 01/2021 - 10/2009
3	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2018 - 04/2013
2	Dermatitis 01/2021 - 12/2018
2	Necrosis 05/2009 - 01/2009
1	Chronic Renal Insufficiency 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Hypersensitivity (Allergy) 01/2019
1	Skin Diseases (Skin Disease) 01/2018
1	Allergic Contact Dermatitis 01/2018
1	Liver Diseases (Liver Disease) 10/2009
1	Sepsis (Septicemia) 08/2009
1	Endotoxemia 08/2009
1	Pancreatitis 05/2009
1	Acute Necrotizing Pancreatitis 05/2009
1	Acute Liver Failure (Fulminant Hepatic Failure) 01/2009

Drug/Important Bio-Agent (IBA)

2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2018
2	CXA-10IBA 01/2021 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 12/2018 - 04/2013
2	Purinergic P2X7 ReceptorsIBA 12/2018 - 04/2013
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2009 - 05/2009
1	Therapeutic UsesIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2019
1	InflammasomesIBA 12/2018
1	AlarminsIBA 12/2018
1	Interleukin-23 (Interleukin 23)IBA 12/2018
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2018
1	Conjugated Linoleic AcidsIBA 01/2018
1	HaptensIBA 01/2018
1	Purinergic Receptors (Receptors, Purine)IBA 04/2013
1	EnzymesIBA 10/2009
1	CytokinesIBA 08/2009
1	LipopolysaccharidesIBA 08/2009
1	HMGB1 Protein (HMG1)IBA 08/2009
1	CeruletideIBA 05/2009
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2009
1	Messenger RNA (mRNA)IBA 05/2009
1	Alanine Transaminase (SGPT)IBA 05/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2009
1	Interleukin-6 (Interleukin 6)IBA 05/2009
1	ethyl pyruvateIBA 05/2009
1	Choline (Choline Chloride)IBA 05/2009
1	EthionineIBA 05/2009
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2009

Therapy/Procedure

1	Injections 01/2018